The Food and Administration (FDA) has authorized use of Ozempic (semaglutide) for the treatment of chronic kidney disease (CKD) in adults with Type 2 diabetes. This groundbreaking approval marks a new frontier for the widely used GLP-1 receptor agonist, beyond blood sugar control and weight loss.
Clinical trials have also demonstrated that in addition to regulating blood sugar levels, Ozempic slows CKD progression, which reduces the risk of kidney failure and cardiovascular disease. This special medication not only targets inflammation quite common in CKD patients, improving one aspect of the metabolic health, but also acts via a dual mechanism of action allowing healthcare professionals to treat diabetes-related kidney disease more effectively. The approval could alter treatment guidelines and significantly benefit patients, the experts said.
As CKD becomes more common among those patients with type 2 diabetes, the broader use of Ozempic will be an important step forward in addressing this public health challenge.
Reference:
- DiaTribe : Ozempic for CKD
- Cleveland Clinic : GLP-1
- Mayo Clinic : CKD
For inquiries about prescription medications, contact our team at Jason’s CanadaDrugstore.com by calling 1-800-226 3784 (CAN-DRUG) for assistance from our patient representatives or a licensed Canadian pharmacist.
This article provides medical information to help understand a condition or treatment plan but is not a diagnosis or treatment recommendation. Contact your doctor if you have concerns or symptoms. In case of emergency, call 911.
Leave a Reply